Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema
Keywords
Abstract
Description
Objective: Uveitis, an inflammatory condition that affects the uvea (iris, ciliary body and choroid) and adjacent structures of the eyes, is an important cause of visual loss. Most cases of uveitis, not related to an infectious agent, are thought to be autoimmune in origin and are effectively treated with medications to suppress the function of the immune system. Efforts to decrease morbidity, reduce the dose of more toxic immunosuppressive drugs, reduce the frequency of recurrences of inflammation and its sequelae are important goals in the treatment of uveitis. A frequent sequela of uveitis is macular edema. Treatment of macular edema in patients with uveitis has been a particular challenge. Current evidence from diabetic macular edema (DME) and vitreomacular traction (VMT) trials suggests that pharmacologically-induced vitreoretinal separation could be a potential treatment for macular edema associated with uveitis. Microplasmin, a truncated form of human plasmin and naturally occurring enzyme that dissolves blood clots, may be a reasonable candidate for the treatment of uveitic macular edema. The objective of this study is to investigate the safety and efficacy of microplasmin as a treatment for uveitic macular edema.
Study Population: Five participants with uveitic macular edema, with or without VMT, will be enrolled. In addition, participants must have no evidence of macular or complete posterior vitreous detachment (PVD) by Optical Coherence Tomography (OCT) or ultrasound.
Design: This Phase I-II, non-randomized, prospective, uncontrolled, single-center study will involve a one-time intravitreal injection of 125 µg in 100 µL of microplasmin. Eligible participants can receive the intravitreal injection on the same day of the baseline examination. Participants will be followed for 24 weeks post-injection.
Outcome Measures: The primary outcome measure related to the safety and tolerability of microplasmin will be assessed by the number and severity of adverse events (AEs) and systemic and ocular toxicities during the study. The secondary outcome measures related to the potential efficacy of an intravitreal injection of microplasmin for macular edema secondary to uveitis will be assessed by a change in central macular thickness from baseline measured by OCT in response to microplasmin at 4 and 12 weeks post-injection, the number of participants achieving macular or complete PVD at 4 and 12 weeks post-injection, the change of ETDRS best-corrected visual acuity (BCVA) and the change of retino-vascular leakage from baseline seen on fluorescein angiography (FA).
Dates
| Last Verified: | 06/30/2018 |
| First Submitted: | 09/01/2010 |
| Estimated Enrollment Submitted: | 09/01/2010 |
| First Posted: | 09/02/2010 |
| Last Update Submitted: | 07/02/2018 |
| Last Update Posted: | 07/30/2018 |
| Date of first submitted results: | 07/09/2012 |
| Date of first submitted QC results: | 07/09/2012 |
| Date of first posted results: | 08/13/2012 |
| Actual Study Start Date: | 12/31/2010 |
| Estimated Primary Completion Date: | 11/30/2011 |
| Estimated Study Completion Date: | 11/30/2011 |
Condition or disease
Intervention/treatment
Drug: Microplasmin
Phase
Arm Groups
| Arm | Intervention/treatment |
|---|---|
| Experimental: Microplasmin | Drug: Microplasmin Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline. |
Eligibility Criteria
| Ages Eligible for Study | 18 Years To 18 Years |
| Sexes Eligible for Study | All |
| Accepts Healthy Volunteers | Yes |
| Criteria | Inclusion Criteria 1. Participant must be 18 years of age or older. 2. Participant must understand and sign the protocol's informed consent document. 3. Participant has a diagnosis of uveitic macular edema that requires treatment in at least one eye (the study eye) and the uveitis in the study eye is deemed clinically quiet by the investigator. 4. Participant has no evidence of macular or complete PVD in the study eye by B-scan ultrasound and OCT. 5. Participant has visual acuity of 20/400 or better in the study eye. 6. Participant has a central macular thickness ≥ 270 microns in the study eye and loss of the normal foveal contour. 7. Participant does not have significant cataract or media opacity in the study eye that makes posterior segment visualization difficult as determined by investigator. 8. Female participants of childbearing potential must not be pregnant or breast-feeding and must have a negative serum pregnancy test at screening and throughout the study. 9. Both female participants of childbearing potential and male participants able to father a child must agree to practice two effective methods of birth control for six months following administration of study medication. Acceptable methods of birth control for this study include hormonal contraception (birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide or surgical sterilization (hysterectomy, tubal ligation or vasectomy). Participants with a hysterectomy or vasectomy (or have a partner with a hysterectomy or vasectomy) are exempt from using two methods of birth control. 10. Participant is willing to comply with the study procedures and return for all study visits. Exclusion Criteria 1. Participant has uncontrolled glaucoma, defined as intraocular pressure >30 mmHg despite treatment with anti-glaucoma medication, in the study eye. 2. Participant has lattice degeneration of the retina in the study eye deemed to be high risk by the investigator. 3. Participant has untreated retinal holes or tears, or a macular hole in the study eye. 4. Participant has a significant active ocular infection in the study eye. 5. Participant had intraocular surgery within the past 90 days or anticipates elective intraocular surgery in the study eye. 6. Participant had an injection of bevacizumab or ranibizumab within the past four weeks in the study eye. 7. Participant had an injection of triamcinolone within the past six weeks in the study eye. 8. Participant has a condition that, in the opinion of the investigator, would preclude participation in the study (e.g., unstable medical status that would pose a significant hazard if investigational therapy was started). 9. Participant has known anaphylaxis to sodium fluoride, or has urticaria, angioedema or an anaphylactoid response to sodium fluorescein dye that cannot be safely pre-medicated with an antihistamine and/or prednisone. |
Outcome
Primary Outcome Measures
1. Number of Adverse Events [24 weeks]
2. Number of Severe Adverse Events [24 weeks]
3. Number of Ocular Adverse Events [24 weeks]
4. Number of Non-ocular Adverse Events [24 weeks]
Secondary Outcome Measures
1. Change in Central Macular Thickness, as Measured by Optical Coherence Tomography (OCT), at 4 Weeks vs. Baseline [Baseline and 4 weeks]
2. Number of Participants Achieving Macular or Complete Posterior Vitreous Detachment (PVT) at 4 Weeks [Baseline and 4 weeks]
3. Change in ETDRS Best-corrected Visual Acuity (BCVA) at 4 Weeks vs. Baseline [Baseline and 4 weeks]
4. Change in ETDRS Best-corrected Visual Acuity (BCVA) at 12 Weeks vs. Baseline [Baseline and 12 Weeks]
5. Change in Retino-vascular Leakage, as Seen on Fluorescein Angiography (FA), at 4 Weeks vs. Baseline [Baseline and 4 weeks]
